TEVA Stock Down 14% Despite Q4 Earnings & Revenues Beat Estimates

Teva Pharmaceutical Industries (TEVA) reported fourth-quarter 2024 adjusted earnings of 71 cents per share, which beat the Zacks Consensus Estimate of 70 cents. Adjusted earnings declined 29% year over year.See the Zacks Earnings Calendar to stay ahead of market-making news.Revenues for the fourth quarter were $4.23 billion, beating the Zacks Consensus Estimate of$4.10 billion. However, total revenues declined 5% from the year-ago quarter on both reported and constant currency basis. The decline is mainly ...